• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services

    7/22/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email

    WARRINGTON, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic partnership with Kraken, a leading global cryptocurrency platform, to provide custody, trading, and over-the-counter (OTC) services for Windtree's BNB Crypto Treasury Strategy. The parties have signed a term sheet, to be memorialized in a definitive agreement following shareholder approval of Windtree's previously announced securities purchase agreement, with potential for up to an additional $140 million in future subscriptions, led by Build and Build Corp.

    This partnership positions Windtree to leverage Kraken's industry-leading security, liquidity, and expertise in digital asset management to support its pioneering BNB-focused treasury strategy. Windtree, the first NASDAQ-listed company offering pure play direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $100 billion), expects the collaboration to enhance its ability to provide secure access to the Binance ecosystem for retail and institutional investors.

    Kraken's robust infrastructure will ensure secure custody and efficient trading of BNB assets, while its OTC desk will facilitate large-scale transactions for Windtree's treasury strategy. This partnership underscores Windtree's commitment to establishing a leading BNB Crypto Treasury Strategy, encompassing custody, security, and yield generation.

    "We are excited to partner with Kraken, a trusted leader in the cryptocurrency industry, to support our groundbreaking BNB strategy," said Jed Latkin, Chief Executive Officer of Windtree. "Kraken's expertise and secure platform will strengthen our ability to deliver unparalleled exposure to the Binance ecosystem, creating significant value for our shareholders."

    "Kraken is proud to partner with Windtree to help expand access to BNB and Binance Smart Chain for a broader audience," said David Olsson, Global Head of Institutional Client Solutions at Kraken. "Our deep liquidity and industry-leading security infrastructure allow us to deliver bespoke solutions tailored to the needs of corporate treasury teams. With qualified custody, a leading staking platform, and seamless OTC execution, we're well-positioned to support Windtree as they execute their digital asset strategy with confidence and precision."

    The Binance Smart Chain (BSC) supports a thriving decentralized finance (DeFi) ecosystem with thousands of decentralized applications (dApps) and millions of users, driven by BNB's high liquidity and average daily trading volumes exceeding $2 billion. This partnership positions Windtree to capitalize on the global growth potential of the Binance ecosystem, particularly in the U.S. market.

    The Kraken term sheet is subject to shareholder approval of Windtree's previously announced securities purchase agreement, led by Build and Build Corp and the satisfaction of other closing conditions. A definitive agreement will be finalized post-closing.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Windtree Therapeutics, Inc.

    Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners.

    About Kraken

    Kraken is a technology platform built on crypto that unlocks access and reduces inefficiencies to drive financial freedom — for the crypto economy and beyond.

    Millions of individuals, professional traders, and institutions around the world use Kraken to trade digital and traditional assets, including cryptocurrencies, national currencies, U.S. futures, and U.S.-listed stocks and ETFs.

    Kraken markets can be monitored and traded via the web or through the Kraken and Kraken Pro iOS and Android apps. Futures platforms by NinjaTrader, a Kraken company, are available on desktop, web, and mobile via www.ninjatrader.com.

    For more information about Kraken, please visit www.kraken.com.

    About Build and Build Corp

    Build and Build Corp is a dynamic company established by Patrick Horsman, Joshua Kruger, and Johnathan Pasch, who together bring over 43 years of expertise in hedge funds and digital asset management. The company is backed by prominent investors, including Off The Chain Capital, Kraken, Galaxy, and Silvermine, supporting its mission to deliver innovative solutions in the financial and digital asset sectors.

    Forward-Looking Statements

    The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: risks related to obtaining shareholder approval for the Build and Build Corp transaction and satisfying the other conditions necessary to consummate the transaction and related transactions, including the Kraken partnership, which cannot be assured; risks associated with the execution and performance of the partnership with Kraken; the Company's ability to manage costs and execute on its operational and budget plans; risks related to the regulatory environment for cryptocurrency transactions; and the Company's ability to develop and maintain its BNB Crypto Treasury Strategy. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

    Contact Information:

    Eric Curtis

    [email protected]

    Lauren Post

    [email protected]



    Primary Logo

    Get the next $WINT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kucharchuk Andrew Albert

    3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    8/5/25 4:43:08 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Kelly Leanne

    3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    1/14/25 4:17:38 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    10/9/24 7:46:52 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    10/9/24 7:46:52 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    9/28/23 7:24:59 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    9/27/23 7:34:59 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

    Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

    6/4/21 6:09:49 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    SEC Filings

    View All

    Windtree Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

    8/20/25 12:15:15 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Windtree Therapeutics Inc.

    10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

    8/19/25 5:29:07 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by Windtree Therapeutics Inc.

    NT 10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

    8/14/25 5:01:48 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

    Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profile seen in previous studies gives Windtree confidence to move forward with a global Phase 3 study WARRINGTON, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners, announced that

    8/11/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

    Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe presentation of heart failure and SCAI Stage C patients have low blood pressure and signs of organ damage due to low blood flow These data provide the Company confidence to move forward with a global Phase 3 trial WARRINGTON, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company with several divisions, including a cryptocurrency treasury strategy and two promisi

    8/5/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

    Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build Corp displaying the underlying demand for the coin globally WARRINGTON, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced large reductions in outstanding shares of its preferred series C and D shares. Only 19

    7/29/25 9:01:29 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Windtree Therapeutics Inc.

    SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 3:40:27 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 8:53:39 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Leadership Updates

    Live Leadership Updates

    View All

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

    WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w

    1/13/25 8:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Windtree Announces Leadership Transition Plan With Industry Veterans

    WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser

    11/14/24 8:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $WINT
    Financials

    Live finance-specific insights

    View All

    Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive

    5/16/25 8:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

    4/15/25 8:00:00 AM ET
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Evofem Reports Fourth Consecutive Year of Net Sales Growth

    -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

    3/24/25 8:30:00 AM ET
    $ADTX
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)